title: Combined intravenous and oral mesna in outpatients treated with ifosfamide.
abstract: OBJECTIVE
  To prevent hemorrhagic cystitis, mesna is typically injected intravenously (i.v.) at the time of an ifosfamide dose and 4 and 8 h later. To simplify outpatient ifosfamide therapy, we gave the second and third mesna doses orally.
  
  
  METHODS
  The mesna doses (400 or 600 mg/m2) were 40% (w/w) of each ifosfamide dose (1.0 or 1.5 g/m2), which was given daily for 5 days. We evaluated urinary mesna excretion and plasma concentrations in ten patients from the beginning of mesna infusion until the time of the second oral dose. The first oral dose was administered at hour 2 in the last six patients to allow time for absorption of mesna.
  
  
  RESULTS
  The rate and amount of mesna excretion was less variable over time and among patients after oral than after i.v. administration. No macrohematuria was observed in these ten patients nor in an additional 50 patients given oral mesna at hours 2 and 8 during at least two cycles of ifosfamide therapy.
  
  
  CONCLUSIONS
  These pharmacokinetic and clinical efficacy data support the use of a combined regimen of i.v. and oral mesna to simplify outpatient ifosfamide administration.
authors.affiliation: Department of Pathology and Laboratory Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Goren
authors.forename: L M
authors.initials: LM
authors.lastname: McKenna
authors.forename: T L
authors.initials: TL
authors.lastname: Goodman
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000493:pharmacokinetics; D003556:Cystitis / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control* / Q000652:urine; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects* / Q000493:pharmacokinetics; D007262:Infusions, Intravenous; D008297:Male; D015080:Mesna / Q000008:administration & dosage* / Q000493:pharmacokinetics; D008875:Middle Aged; D016896:Treatment Outcome; D001743:Urinary Bladder / Q000187:drug effects*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D015080:Mesna; D007069:Ifosfamide